Cannabis Science Receives New Photos & Positive Feedback from Patient Three & an Oncologist about his Severe Squamous Cell Ca...
11 April 2012 - 10:08PM
Business Wire
Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S.
biotech company developing pharmaceutical cannabis (marijuana)
products, is pleased to provide new photographs of the existing
treatment for patient three who has a “worst case” of treatment
resistant, Squamous Cell Carcinoma. Cannabis Science has received
positive feedback from both the patient and his Oncologist. These
photos show the progressive reduction of the tumor masses that has
occurred within the months of treatment.
Oncologists have stated that this is the worst case of squamous
cell carcinoma, and last week, the patient’s oncologist said the
results from the topical cannabis extract are “astonishing.” So
instead of needing any surgery this month he is to go back and see
the oncologist in June. The patient's wife, who could not even look
at her husband’s head months ago, has stated that it looks as if
75% of the tumors masses are gone.
Since Cannabis Science has been working with this patient
extensively, Dr. Robert Melamede has provided lots of support and
expert scientific advice during the treatment process. Patient
three came to Cannabis Science with hope to find a treatment that
would work. Due to his extremely severe case of squamous cell
carcinoma, his surgeon wanted to remove his scalp and a good
portion of his skull. Instead he opted for 135 radiation
treatments, but the remaining tumors became radiation and
chemotherapy resistant. Dr. Robert Melamede informs that, “Cannabis
extracts have the unique ability to holistically improve health.
They simultaneously modify numerous biochemical pathways to
produces a healthy concerted action.”
You can view these new photos on the Cannabis Science website
www.cannabisscience.com and click the button “View Images of 3rd
Self-Medicated Patient & His Apparent Success.” You can read
more news on this 3rd patient as well on the Cannabis Science
website www.cannabisscience.com and click on the breaking news
button where you will find all the cancer related and updated
patient news.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.